Physician profile
Fortuna Abebe
NPI 1073185278
$2,320.89
in general payments reported to CMS, 2019-2025
16 companies · $607 in 2025
The $607 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $254 · 2022: $451 · 2023: $450 · 2024: $559 · 2025: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $469.11 | 2022-2025 | Total30, Rocklatan, Clareon |
| Abbvie INC. | $437.36 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Bausch & Lomb Americas INC. | $351.42 | 2022-2025 | Infuse, Xiidra, Miebo |
| Coopervision INC. | $273.58 | 2022-2024 | Myday Contact Lens |
| Aerie Pharmaceuticals, INC. | $149.18 | 2021 | |
| Novartis Pharmaceuticals Corporation | $108.72 | 2022 | |
| Glaukos Corporation | $107.97 | 2024 | Idose |
| Allergan, INC. | $88.98 | 2021 | |
| Astellas Pharma US INC | $84.19 | 2024-2025 | Izervay |
| Tarsus Pharmaceuticals, INC. | $75.80 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $56.99 | 2023-2024 | Tyrvaya, Ryzumvi |
| Dompe US, INC. | $34.01 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $32.03 | 2022 | |
| Harrow Eye, LLC | $18.05 | 2025 | Vevye |
| Sun Pharmaceutical Industries INC. | $17.85 | 2023 | Cequa |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $15.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fortuna Abebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.